



EMORY
UNIVERSITY
SCHOOL OF
MEDICINE

Department of Psychiatry and Behavioral Sciences

Charles B. Nemeroff, MD, PhD
Reunette W. Harris Professor and Chairman

December 21, 2006

Michael M.E. Johns, M.D.
Executive Vice President for Health Affairs
4th Floor WHSCAB

Thomas J. Lawley, M.D.
Dean, Emory University School of Medicine
3rd Floor, WHSCAB

Dear Drs. Johns and Lawley:

This is the summary letter that you requested in follow-up to our meeting on December 18, 2006 concerning my participation in activities outside of Emory. I have summarized in the space below the consensus we reached and I have copied Brenda Seiton, J.D., Assistant Dean, on this letter.

My outside activities will be limited to the following: I will serve on Scientific Advisory Boards for five companies. They include 1) PharmaNeuroBoosting based in Belgium 2) Janssen/OrthoMcNeil, 3) Forest Laboratories, 4) AstraZeneca and 5) Quintiles. New contracts concerning my membership on these scientific advisory boards will be submitted to Brenda Seiton for approval. As you know, I have been copying both of you on my emails to various companies indicating my resignation from their scientific advisory boards or consultancy agreements. Thus far, I have resigned from all such activities with 1) Pfizer, 2) Bristol-Myers Squibb, 3) Cyberonics, 4) Eli Lilly, 5) Neuronetics, 6) Lundbeck, 7) Abbott, 8) SK-Biopharmaceuticals and 9) Solvay.

In addition, I will be sending letters of resignation in the next few days to Wyeth Pharmaceuticals, Corcept, Ono Pharmaceuticals, Acadia, Otsuka and UCB Pharma that will cover all current and past consultant agreements and scientific advisory boards. 2) I will not serve as principal investigator or co-investigator of any pharmaceutical company-sponsored clinical trials or preclinical laboratory research. I will also not participate in any pharmaceutical-sponsored "promotional" lectures or speaker's bureaus. I will continue with accredited continuing medical education (CME) activities. Any CME contracts will also be forwarded to Brenda Seiton for approval. As per your letter of November 3, 2006. I will continue to serve on the Board of Directors of Novadel Pharmaceuticals and to hold a small equity position in CeneRx and Reevax. At the appropriate time and at Dr. Lawley's discretion, I will discuss these decisions at the Council of Chairs meeting, and I intend to do so at the next departmental faculty meeting as well.

Emory University School of Medicine
Woodruff Memorial Research Building
101 Woodruff Circle, Suite 4000
Atlanta, Georgia 30322

The Robert W. Woodruff Health Sciences Center
An equal opportunity, affirmative action university

Tel: [REDACTED]
Fax: [REDACTED]
[REDACTED]@emory.edu